Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-07921585 Monotherapy and Combination Therapy in Advanced Solid Tumors
NCT06580938Phase 1Terminated
- Sponsor
- Pfizer
- Start
- Nov 2024
- Primary completion
- Jul 2025
- Modality
- Fc Fusion Proteins, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label trial of PF-07921585 in non-small cell lung cancer (NSCLC), colorectal cancer (CRC), bladder cancer and 3 more (3 arms), sponsored by Pfizer. Primary endpoints: Dose-Limiting Toxicity, Treatment Emergent Adverse Events and Serious Adverse Events and 2 more. Started Nov 2024; status: terminated.
02
Drugs
PF-07921585
03
Conditions
non-small cell lung cancer (NSCLC)colorectal cancer (CRC)bladder cancermelanomarenal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT06580938.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06580938.